South & Central America Antibody Drug Conjugates Market Size and Forecast (2021 - 2031)
The South and Central America Antibody Drug Conjugates (ADC) market is projected to grow significantly, reaching approximately US$ 1,062.2 million by 2031, up from US$ 254.8 million in 2023, reflecting a compound annual growth rate (CAGR) of 19.5% from 2023 to 2031.
Executive Summary and Market Analysis
The ADC market in South and Central America, which includes Brazil, Argentina, and other regions, is experiencing robust growth driven by several factors. Increased awareness of cancer and its rising incidence has heightened the demand for advanced and targeted therapies like ADCs. Governments and healthcare organizations are actively promoting early detection and treatment, further propelling market expansion. Additionally, the surge in clinical trials in Brazil and Argentina is accelerating research and development, leading to the introduction of innovative ADC therapies. Supportive government policies and recent oncology drug approvals are also contributing to market growth. Brazil, with its well-established healthcare infrastructure and investment in biotechnology, leads the market, followed by Argentina and other countries that are improving healthcare access and forming partnerships with global pharmaceutical firms.
Strategic Insights
Market Segmentation Analysis
The expansion into new indications presents significant opportunities within the ADC market. ADCs are designed to deliver cytotoxic agents directly to cancer cells while minimizing damage to healthy tissues, making them highly versatile. This versatility allows for the exploration of ADC applications beyond their initial focus on hematological malignancies and certain solid tumors. Many cancers currently lack effective treatment options, and the introduction of ADCs targeting new biomarkers can offer innovative therapies for these challenging conditions. For example, in Brazil, the indication for trastuzumab deruxtecan was expanded in November 2022 to include patients with metastatic or unresectable HER2-low breast cancer, significantly increasing the number of eligible patients and the projected treatment costs.
Collaborations between pharmaceutical companies and research institutions are fostering innovation in ADC development, focusing on identifying novel targets and optimizing linker technologies to enhance efficacy and safety. With the discovery of new targets, ADCs are being investigated for a broader range of cancer types, addressing unmet medical needs and benefiting from favorable regulatory conditions. This positions ADCs as a crucial component of future targeted cancer therapies.
Country Insights
The ADC market is segmented by country into Brazil, Argentina, and the Rest of South and Central America, with Brazil holding the largest market share in 2023. The increasing incidence of cancers, particularly breast and lung cancers, has led to a heightened demand for effective treatment options in Brazil. The approval and introduction of ADCs like Kadcyla and Adcetris have provided oncologists with advanced tools to target cancer cells, improving patient outcomes. The Brazilian government is implementing policies to enhance access to cancer treatments, including ADCs. For instance, in September 2022, the Ministry of Health announced coverage for trastuzumab emtansine (Kadcyla) under the Unified Health System for HER2-positive breast cancer, providing it free of charge to patients.
Company Profiles
Key players in the South and Central America ADC market include GSK Plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Bristol-Myers Squibb Co, Johnson & Johnson, Takeda Pharmaceutical Co Ltd, AstraZeneca Plc, Astellas Pharma Inc, AbbVie Inc, Merck KGaA, Gilead Sciences Inc, BioNTech SE, Daiichi Sankyo Co Ltd, RemeGen Co Ltd, and ADC Therapeutics SA. These companies are employing various strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence and offer innovative products.
Executive Summary and Market Analysis
The ADC market in South and Central America, which includes Brazil, Argentina, and other regions, is experiencing robust growth driven by several factors. Increased awareness of cancer and its rising incidence has heightened the demand for advanced and targeted therapies like ADCs. Governments and healthcare organizations are actively promoting early detection and treatment, further propelling market expansion. Additionally, the surge in clinical trials in Brazil and Argentina is accelerating research and development, leading to the introduction of innovative ADC therapies. Supportive government policies and recent oncology drug approvals are also contributing to market growth. Brazil, with its well-established healthcare infrastructure and investment in biotechnology, leads the market, followed by Argentina and other countries that are improving healthcare access and forming partnerships with global pharmaceutical firms.
Strategic Insights
Market Segmentation Analysis
- By Technology: The market is divided into Cleavable Linker and Non-cleavable Linker, with Cleavable Linker holding a larger market share in 2023.
- By Application: The ADC market is segmented into Blood Cancer, Brain Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, and Others, with Breast Cancer dominating the market share in 2023.
- By Target: The market is categorized into HER2, CD22, CD30, and Others, with Others holding the largest share in 2023.
- By Distribution Channel: The market is segmented into Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies, with Hospital Pharmacies leading in market share in 2023.
The expansion into new indications presents significant opportunities within the ADC market. ADCs are designed to deliver cytotoxic agents directly to cancer cells while minimizing damage to healthy tissues, making them highly versatile. This versatility allows for the exploration of ADC applications beyond their initial focus on hematological malignancies and certain solid tumors. Many cancers currently lack effective treatment options, and the introduction of ADCs targeting new biomarkers can offer innovative therapies for these challenging conditions. For example, in Brazil, the indication for trastuzumab deruxtecan was expanded in November 2022 to include patients with metastatic or unresectable HER2-low breast cancer, significantly increasing the number of eligible patients and the projected treatment costs.
Collaborations between pharmaceutical companies and research institutions are fostering innovation in ADC development, focusing on identifying novel targets and optimizing linker technologies to enhance efficacy and safety. With the discovery of new targets, ADCs are being investigated for a broader range of cancer types, addressing unmet medical needs and benefiting from favorable regulatory conditions. This positions ADCs as a crucial component of future targeted cancer therapies.
Country Insights
The ADC market is segmented by country into Brazil, Argentina, and the Rest of South and Central America, with Brazil holding the largest market share in 2023. The increasing incidence of cancers, particularly breast and lung cancers, has led to a heightened demand for effective treatment options in Brazil. The approval and introduction of ADCs like Kadcyla and Adcetris have provided oncologists with advanced tools to target cancer cells, improving patient outcomes. The Brazilian government is implementing policies to enhance access to cancer treatments, including ADCs. For instance, in September 2022, the Ministry of Health announced coverage for trastuzumab emtansine (Kadcyla) under the Unified Health System for HER2-positive breast cancer, providing it free of charge to patients.
Company Profiles
Key players in the South and Central America ADC market include GSK Plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Bristol-Myers Squibb Co, Johnson & Johnson, Takeda Pharmaceutical Co Ltd, AstraZeneca Plc, Astellas Pharma Inc, AbbVie Inc, Merck KGaA, Gilead Sciences Inc, BioNTech SE, Daiichi Sankyo Co Ltd, RemeGen Co Ltd, and ADC Therapeutics SA. These companies are employing various strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence and offer innovative products.
1. INTRODUCTION
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. ANTIBODY DRUG CONJUGATES MARKET LANDSCAPE
4.1 PEST Analysis
4.2 Ecosystem Analysis
4.2.1 Raw Materials and Sourcing
4.2.2 Manufacturing Processes
4.2.3 Regulatory Compliance
4.2.4 Distribution and Logistics
4.2.5 List of Vendors in the Value Chain
5. SOUTH AND CENTRAL AMERICA ANTIBODY DRUG CONJUGATES MARKET - KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. ANTIBODY DRUG CONJUGATES MARKET - SOUTH AND CENTRAL AMERICA MARKET ANALYSIS
6.1 South and Central America Antibody Drug Conjugates Market Revenue (US$ Million), 2023 - 2031
6.2 South and Central America Antibody Drug Conjugates Market Forecast and Analysis
7. SOUTH AND CENTRAL AMERICA ANTIBODY DRUG CONJUGATES MARKET REVENUE ANALYSIS - BY TECHNOLOGY
7.1 Cleavable Linker
7.1.1 Overview
7.1.2 Cleavable Linker: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 Non-cleavable Linker
7.2.1 Overview
7.2.2 Non-cleavable Linker: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. SOUTH AND CENTRAL AMERICA ANTIBODY DRUG CONJUGATES MARKET REVENUE ANALYSIS - BY APPLICATION
8.1 Blood Cancer
8.1.1 Overview
8.1.2 Blood Cancer: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 Brain Cancer
8.2.1 Overview
8.2.2 Brain Cancer: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.3 Breast Cancer
8.3.1 Overview
8.3.2 Breast Cancer: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.4 Ovarian Cancer
8.4.1 Overview
8.4.2 Ovarian Cancer: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.5 Lung Cancer
8.5.1 Overview
8.5.2 Lung Cancer: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. SOUTH AND CENTRAL AMERICA ANTIBODY DRUG CONJUGATES MARKET REVENUE ANALYSIS - BY TARGET
9.1 HER2
9.1.1 Overview
9.1.2 HER2: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 CD22
9.2.1 Overview
9.2.2 CD22: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.3 CD30
9.3.1 Overview
9.3.2 CD30: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.4 Others
9.4.1 Overview
9.4.2 Others: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10. SOUTH AND CENTRAL AMERICA ANTIBODY DRUG CONJUGATES MARKET REVENUE ANALYSIS - BY DISTRIBUTION CHANNEL
10.1 Retail Pharmacies
10.1.1 Overview
10.1.2 Retail Pharmacies: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.2 Hospital Pharmacies
10.2.1 Overview
10.2.2 Hospital Pharmacies: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.3 Online Pharmacies
10.3.1 Overview
10.3.2 Online Pharmacies: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11. SOUTH AND CENTRAL AMERICA ANTIBODY DRUG CONJUGATES MARKET - COUNTRY ANALYSIS
11.1 South and Central America
11.1.1 South and Central America Antibody Drug Conjugates Market Revenue and Forecast and Analysis - by Country
11.1.1.1 South and Central America Antibody Drug Conjugates Market Revenue and Forecast and Analysis - by Country
11.1.2.2 Brazil: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.1.2.2.1 Brazil: South and Central America Antibody Drug Conjugates Market Share - by Technology
11.1.2.2.2 Brazil: South and Central America Antibody Drug Conjugates Market Share - by Application
11.1.2.2.3 Brazil: South and Central America Antibody Drug Conjugates Market Share - by Target
11.1.2.2.4 Brazil: South and Central America Antibody Drug Conjugates Market Share - by Distribution Channel
11.2.3.3 Argentina: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.2.3.3.1 Argentina: South and Central America Antibody Drug Conjugates Market Share - by Technology
11.2.3.3.2 Argentina: South and Central America Antibody Drug Conjugates Market Share - by Application
11.2.3.3.3 Argentina: South and Central America Antibody Drug Conjugates Market Share - by Target
11.2.3.3.4 Argentina: South and Central America Antibody Drug Conjugates Market Share - by Distribution Channel
11.3.4.4 Rest of South and Central America: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.3.4.4.1 Rest of South and Central America: South and Central America Antibody Drug Conjugates Market Share - by Technology
11.3.4.4.2 Rest of South and Central America: South and Central America Antibody Drug Conjugates Market Share - by Application
11.3.4.4.3 Rest of South and Central America: South and Central America Antibody Drug Conjugates Market Share - by Target
11.3.4.4.4 Rest of South and Central America: South and Central America Antibody Drug Conjugates Market Share - by Distribution Channel
12 COMPETITIVE LANDSCAPE
12.1 Heat Map Analysis by Key Players
12.2 Company Positioning & Concentration
13 INDUSTRY LANDSCAPE
13.1 Overview
13.2 New Product Development
13.3 Merger and Acquisition
13.4 Other Strategic Developments
14 COMPANY PROFILES
14.1 GSK Plc
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 F. Hoffmann-La Roche Ltd
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Pfizer Inc
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Bristol-Myers Squibb Co
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Johnson & Johnson
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Takeda Pharmaceutical Co Ltd
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 AstraZeneca Plc
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Astellas Pharma Inc
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 AbbVie Inc
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 Merck KGaA
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
14.11 Gilead Sciences Inc
14.11.1 Key Facts
14.11.2 Business Description
14.11.3 Products and Services
14.11.4 Financial Overview
14.11.5 SWOT Analysis
14.11.6 Key Developments
14.12 BioNTech SE
14.12.1 Key Facts
14.12.2 Business Description
14.12.3 Products and Services
14.12.4 Financial Overview
14.12.5 SWOT Analysis
14.12.6 Key Developments
14.13 Daiichi Sankyo Co Ltd
14.13.1 Key Facts
14.13.2 Business Description
14.13.3 Products and Services
14.13.4 Financial Overview
14.13.5 SWOT Analysis
14.13.6 Key Developments
14.14 RemeGen Co Ltd
14.14.1 Key Facts
14.14.2 Business Description
14.14.3 Products and Services
14.14.4 Financial Overview
14.14.5 SWOT Analysis
14.14.6 Key Developments
14.15 ADC Therapeutics SA
14.15.1 Key Facts
14.15.2 Business Description
14.15.3 Products and Services
14.15.4 Financial Overview
14.15.5 SWOT Analysis
14.15.6 Key Developments
15. APPENDIX
15.1 About The Insight Partners
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. ANTIBODY DRUG CONJUGATES MARKET LANDSCAPE
4.1 PEST Analysis
4.2 Ecosystem Analysis
4.2.1 Raw Materials and Sourcing
4.2.2 Manufacturing Processes
4.2.3 Regulatory Compliance
4.2.4 Distribution and Logistics
4.2.5 List of Vendors in the Value Chain
5. SOUTH AND CENTRAL AMERICA ANTIBODY DRUG CONJUGATES MARKET - KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. ANTIBODY DRUG CONJUGATES MARKET - SOUTH AND CENTRAL AMERICA MARKET ANALYSIS
6.1 South and Central America Antibody Drug Conjugates Market Revenue (US$ Million), 2023 - 2031
6.2 South and Central America Antibody Drug Conjugates Market Forecast and Analysis
7. SOUTH AND CENTRAL AMERICA ANTIBODY DRUG CONJUGATES MARKET REVENUE ANALYSIS - BY TECHNOLOGY
7.1 Cleavable Linker
7.1.1 Overview
7.1.2 Cleavable Linker: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 Non-cleavable Linker
7.2.1 Overview
7.2.2 Non-cleavable Linker: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. SOUTH AND CENTRAL AMERICA ANTIBODY DRUG CONJUGATES MARKET REVENUE ANALYSIS - BY APPLICATION
8.1 Blood Cancer
8.1.1 Overview
8.1.2 Blood Cancer: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 Brain Cancer
8.2.1 Overview
8.2.2 Brain Cancer: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.3 Breast Cancer
8.3.1 Overview
8.3.2 Breast Cancer: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.4 Ovarian Cancer
8.4.1 Overview
8.4.2 Ovarian Cancer: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.5 Lung Cancer
8.5.1 Overview
8.5.2 Lung Cancer: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. SOUTH AND CENTRAL AMERICA ANTIBODY DRUG CONJUGATES MARKET REVENUE ANALYSIS - BY TARGET
9.1 HER2
9.1.1 Overview
9.1.2 HER2: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 CD22
9.2.1 Overview
9.2.2 CD22: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.3 CD30
9.3.1 Overview
9.3.2 CD30: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.4 Others
9.4.1 Overview
9.4.2 Others: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10. SOUTH AND CENTRAL AMERICA ANTIBODY DRUG CONJUGATES MARKET REVENUE ANALYSIS - BY DISTRIBUTION CHANNEL
10.1 Retail Pharmacies
10.1.1 Overview
10.1.2 Retail Pharmacies: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.2 Hospital Pharmacies
10.2.1 Overview
10.2.2 Hospital Pharmacies: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.3 Online Pharmacies
10.3.1 Overview
10.3.2 Online Pharmacies: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11. SOUTH AND CENTRAL AMERICA ANTIBODY DRUG CONJUGATES MARKET - COUNTRY ANALYSIS
11.1 South and Central America
11.1.1 South and Central America Antibody Drug Conjugates Market Revenue and Forecast and Analysis - by Country
11.1.1.1 South and Central America Antibody Drug Conjugates Market Revenue and Forecast and Analysis - by Country
11.1.2.2 Brazil: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.1.2.2.1 Brazil: South and Central America Antibody Drug Conjugates Market Share - by Technology
11.1.2.2.2 Brazil: South and Central America Antibody Drug Conjugates Market Share - by Application
11.1.2.2.3 Brazil: South and Central America Antibody Drug Conjugates Market Share - by Target
11.1.2.2.4 Brazil: South and Central America Antibody Drug Conjugates Market Share - by Distribution Channel
11.2.3.3 Argentina: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.2.3.3.1 Argentina: South and Central America Antibody Drug Conjugates Market Share - by Technology
11.2.3.3.2 Argentina: South and Central America Antibody Drug Conjugates Market Share - by Application
11.2.3.3.3 Argentina: South and Central America Antibody Drug Conjugates Market Share - by Target
11.2.3.3.4 Argentina: South and Central America Antibody Drug Conjugates Market Share - by Distribution Channel
11.3.4.4 Rest of South and Central America: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.3.4.4.1 Rest of South and Central America: South and Central America Antibody Drug Conjugates Market Share - by Technology
11.3.4.4.2 Rest of South and Central America: South and Central America Antibody Drug Conjugates Market Share - by Application
11.3.4.4.3 Rest of South and Central America: South and Central America Antibody Drug Conjugates Market Share - by Target
11.3.4.4.4 Rest of South and Central America: South and Central America Antibody Drug Conjugates Market Share - by Distribution Channel
12 COMPETITIVE LANDSCAPE
12.1 Heat Map Analysis by Key Players
12.2 Company Positioning & Concentration
13 INDUSTRY LANDSCAPE
13.1 Overview
13.2 New Product Development
13.3 Merger and Acquisition
13.4 Other Strategic Developments
14 COMPANY PROFILES
14.1 GSK Plc
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 F. Hoffmann-La Roche Ltd
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Pfizer Inc
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Bristol-Myers Squibb Co
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Johnson & Johnson
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Takeda Pharmaceutical Co Ltd
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 AstraZeneca Plc
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Astellas Pharma Inc
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 AbbVie Inc
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 Merck KGaA
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
14.11 Gilead Sciences Inc
14.11.1 Key Facts
14.11.2 Business Description
14.11.3 Products and Services
14.11.4 Financial Overview
14.11.5 SWOT Analysis
14.11.6 Key Developments
14.12 BioNTech SE
14.12.1 Key Facts
14.12.2 Business Description
14.12.3 Products and Services
14.12.4 Financial Overview
14.12.5 SWOT Analysis
14.12.6 Key Developments
14.13 Daiichi Sankyo Co Ltd
14.13.1 Key Facts
14.13.2 Business Description
14.13.3 Products and Services
14.13.4 Financial Overview
14.13.5 SWOT Analysis
14.13.6 Key Developments
14.14 RemeGen Co Ltd
14.14.1 Key Facts
14.14.2 Business Description
14.14.3 Products and Services
14.14.4 Financial Overview
14.14.5 SWOT Analysis
14.14.6 Key Developments
14.15 ADC Therapeutics SA
14.15.1 Key Facts
14.15.2 Business Description
14.15.3 Products and Services
14.15.4 Financial Overview
14.15.5 SWOT Analysis
14.15.6 Key Developments
15. APPENDIX
15.1 About The Insight Partners
LIST OF TABLES
Table 1. South and Central America Antibody Drug Conjugates Market Segmentation
Table 2. List of Vendors
Table 3. South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Technology
Table 5. South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 6. South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Target
Table 7. South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 8. South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 9. Brazil: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Technology
Table 10. Brazil: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 11. Brazil: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Target
Table 12. Brazil: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 13. Argentina: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Technology
Table 14. Argentina: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 15. Argentina: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Target
Table 16. Argentina: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 17. Rest of South and Central America: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Technology
Table 18. Rest of South and Central America: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 19. Rest of South and Central America: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Target
Table 20. Rest of South and Central America: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 21. Heat Map Analysis by Key Players
Table 1. South and Central America Antibody Drug Conjugates Market Segmentation
Table 2. List of Vendors
Table 3. South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Technology
Table 5. South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 6. South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Target
Table 7. South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 8. South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 9. Brazil: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Technology
Table 10. Brazil: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 11. Brazil: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Target
Table 12. Brazil: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 13. Argentina: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Technology
Table 14. Argentina: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 15. Argentina: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Target
Table 16. Argentina: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 17. Rest of South and Central America: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Technology
Table 18. Rest of South and Central America: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 19. Rest of South and Central America: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Target
Table 20. Rest of South and Central America: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 21. Heat Map Analysis by Key Players
LIST OF FIGURES
Figure 1. South and Central America Antibody Drug Conjugates Market Segmentation - Country
Figure 2. PEST Analysis
Figure 3. Ecosystem: Antibody Drug Conjugates Market
Figure 4. South and Central America Antibody Drug Conjugates Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. South and Central America Antibody Drug Conjugates Market Revenue (US$ Million), 2023 - 2031
Figure 7. South and Central America Antibody Drug Conjugates Market Share (%) - by Technology, 2023 and 2031
Figure 8. Cleavable Linker: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. Non-cleavable Linker: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. South and Central America Antibody Drug Conjugates Market Share (%) - by Application, 2023 and 2031
Figure 11. Blood Cancer: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 12. Brain Cancer: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. Breast Cancer: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 14. Ovarian Cancer: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 15. Lung Cancer: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 16. Others: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 17. South and Central America Antibody Drug Conjugates Market Share (%) - by Target, 2023 and 2031
Figure 18. HER2: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. CD22: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 20. CD30: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 21. Others: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 22. South and Central America Antibody Drug Conjugates Market Share (%) - by Distribution Channel, 2023 and 2031
Figure 23. Retail Pharmacies: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 24. Hospital Pharmacies: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 25. Online Pharmacies: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 26. South and Central America Antibody Drug Conjugates Market Breakdown by Key Countries, 2023 and 2031 (%)
Figure 27. Brazil: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 28. Argentina: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 29. Rest of South and Central America: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 30. Company Positioning & Concentration
Figure 1. South and Central America Antibody Drug Conjugates Market Segmentation - Country
Figure 2. PEST Analysis
Figure 3. Ecosystem: Antibody Drug Conjugates Market
Figure 4. South and Central America Antibody Drug Conjugates Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. South and Central America Antibody Drug Conjugates Market Revenue (US$ Million), 2023 - 2031
Figure 7. South and Central America Antibody Drug Conjugates Market Share (%) - by Technology, 2023 and 2031
Figure 8. Cleavable Linker: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. Non-cleavable Linker: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. South and Central America Antibody Drug Conjugates Market Share (%) - by Application, 2023 and 2031
Figure 11. Blood Cancer: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 12. Brain Cancer: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. Breast Cancer: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 14. Ovarian Cancer: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 15. Lung Cancer: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 16. Others: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 17. South and Central America Antibody Drug Conjugates Market Share (%) - by Target, 2023 and 2031
Figure 18. HER2: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. CD22: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 20. CD30: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 21. Others: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 22. South and Central America Antibody Drug Conjugates Market Share (%) - by Distribution Channel, 2023 and 2031
Figure 23. Retail Pharmacies: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 24. Hospital Pharmacies: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 25. Online Pharmacies: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 26. South and Central America Antibody Drug Conjugates Market Breakdown by Key Countries, 2023 and 2031 (%)
Figure 27. Brazil: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 28. Argentina: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 29. Rest of South and Central America: South and Central America Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 30. Company Positioning & Concentration
